Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
Public ClinicalTrials.gov record NCT02663193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Two-arm, Prospective, Observational Study to Characterize the Tolerability of Treatment With Enzalutamide or Abiraterone Acetate (With Prednisone) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to characterize the tolerability profiles of enzalutamide and abiraterone acetate (with prednisone) -with specific focus on central nervous system (CNS) tolerability-and quality of life (QoL) after approximately 2 months of participants starting treatment with one of these agents for metastatic castration-resistant prostate cancer (mCRPC).
Study identification
- NCT ID
- NCT02663193
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2015 (Type not available)
- Primary completion
- Jan 2017 (Actual)
- Completion
- Jan 2017 (Actual)
- Last update posted
- Feb 3, 2025
2015 – 2017
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Homewood | Alabama | — | — |
| Not listed | La Mesa | California | — | — |
| Not listed | Wheat Ridge | Colorado | — | — |
| Not listed | Daytona Beach | Florida | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Jeffersonville | Indiana | — | — |
| Not listed | Saint Clair Shores | Michigan | — | — |
| Not listed | Englewood | New Jersey | — | — |
| Not listed | Lawrenceville | New Jersey | — | — |
| Not listed | Morristown | New Jersey | — | — |
| Not listed | Poughkeepsie | New York | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | Middleburg Heights | Ohio | — | — |
| Not listed | Springfield | Oregon | — | — |
| Not listed | Bala-Cynwyd | Pennsylvania | — | — |
| Not listed | Lancaster | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Myrtle Beach | South Carolina | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Virginia Beach | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02663193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2025 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02663193 live on ClinicalTrials.gov.